Filippo Galli1, Michela Varani2, Chiara Lauri2, Guido Gentiloni Silveri2, Livia Onofrio3, Alberto Signore2. 1. Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy. filippo.galli@hotmail.com. 2. Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy. 3. Medical Oncology B, Department of Radiology and Pathology, "Sapienza" University of Rome, Rome, Italy.
Abstract
BACKGROUND: The understanding of the role of different immune cell subsets that infiltrate tumors can help researchers in developing new targeted immunotherapies to reactivate or reprogram them against cancer. In addition to conventional drugs, new cell-based therapies, like adoptive cell transfer, proved to be successful in humans. Indeed, after the approval of anti-CD19 CAR-T cell therapy, researchers are trying to extend this approach to other cancer or cell types. MAIN BODY: This review focuses on the different approaches to non-invasively monitor the biodistribution, trafficking and fate of immune therapeutic cells, evaluating their efficacy at preclinical and clinical stages. PubMed and Scopus databases were searched for published articles on the imaging of cell tracking in humans and preclinical models. CONCLUSION: Labelling specific immune cell subtypes with specific radiopharmaceuticals, contrast agents or optical probes can elucidate new biological mechanisms or predict therapeutic outcome of adoptive cell transfer therapies. To date, no technique is considered the gold standard to image immune cells in adoptive cell transfer therapies.
BACKGROUND: The understanding of the role of different immune cell subsets that infiltrate tumors can help researchers in developing new targeted immunotherapies to reactivate or reprogram them against cancer. In addition to conventional drugs, new cell-based therapies, like adoptive cell transfer, proved to be successful in humans. Indeed, after the approval of anti-CD19 CAR-T cell therapy, researchers are trying to extend this approach to other cancer or cell types. MAIN BODY: This review focuses on the different approaches to non-invasively monitor the biodistribution, trafficking and fate of immune therapeutic cells, evaluating their efficacy at preclinical and clinical stages. PubMed and Scopus databases were searched for published articles on the imaging of cell tracking in humans and preclinical models. CONCLUSION: Labelling specific immune cell subtypes with specific radiopharmaceuticals, contrast agents or optical probes can elucidate new biological mechanisms or predict therapeutic outcome of adoptive cell transfer therapies. To date, no technique is considered the gold standard to image immune cells in adoptive cell transfer therapies.
Authors: X Michalet; F F Pinaud; L A Bentolila; J M Tsay; S Doose; J J Li; G Sundaresan; A M Wu; S S Gambhir; S Weiss Journal: Science Date: 2005-01-28 Impact factor: 47.728
Authors: Erik F J de Vries; Manel Roca; Francois Jamar; Ora Israel; Alberto Signore Journal: Eur J Nucl Med Mol Imaging Date: 2010-04 Impact factor: 9.236
Authors: Martina Rudelius; Heike E Daldrup-Link; Ulrich Heinzmann; Guido Piontek; Marcus Settles; Thomas M Link; Jürgen Schlegel Journal: Eur J Nucl Med Mol Imaging Date: 2003-02-04 Impact factor: 9.236
Authors: Taeho Kim; Eric Momin; Jonghoon Choi; Kristy Yuan; Hasan Zaidi; Jaeyun Kim; Mihyun Park; Nohyun Lee; Michael T McMahon; Alfredo Quinones-Hinojosa; Jeff W M Bulte; Taeghwan Hyeon; Assaf A Gilad Journal: J Am Chem Soc Date: 2011-02-11 Impact factor: 15.419
Authors: Ryan Schlimgen; John Howard; Dawn Wooley; Maureen Thompson; Lindsey R Baden; Otto O Yang; David C Christiani; Gustavo Mostoslavsky; David V Diamond; Elizabeth Gilman Duane; Karen Byers; Thomas Winters; Jeffrey A Gelfand; Gary Fujimoto; T Warner Hudson; Jatin M Vyas Journal: J Occup Environ Med Date: 2016-12 Impact factor: 2.162